Cellectar Biosciences, Inc. Stock Split Ratio
Cellectar Biosciences, Inc. (CLRB) had Stock Split Ratio of 3.30% as of 2025-06-24, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-08-13
- 2025-06-24: Stockholders' Equity Note, Stock Split, Conversion Ratio 3.30%.
- 2025-06-18: Stockholders' Equity Note, Stock Split, Conversion Ratio 3.30%.
- 2025-06-10: Stockholders' Equity Note, Stock Split, Conversion Ratio 3.30%.
- 2022-06-27: Stockholders' Equity Note, Stock Split, Conversion Ratio 10.00%; Stockholders' Equity Note, Stock Split, Conversion Ratio as first filed 1000.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio as first filed |
|---|---|---|
| 2025-06-24 | 3.30% 10-Q · filed 2026-08-13 | |
| 2025-06-18 | 3.30% 10-Q · filed 2026-08-13 | |
| 2025-06-10 | 3.30% 10-Q · filed 2025-08-14 | |
| 2022-06-27 | 10.00% 10-Q · filed 2023-11-13 | 1000.00% 10-Q · filed 2022-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |